Ray Co., Ltd. (KOSDAQ:228670)
 5,250.00
 -10.00 (-0.19%)
  Oct 31, 2025, 3:30 PM KST
Ray Co., Ltd. Revenue
Ray Co., Ltd. had revenue of 27.51B KRW in the quarter ending June 30, 2025, with 11.16% growth. This brings the company's revenue in the last twelve months to 89.70B, down -30.26% year-over-year. In the year 2024, Ray Co., Ltd. had annual revenue of 79.84B, down -45.27%.
Revenue (ttm) 
 89.70B
Revenue Growth 
 -30.26%
P/S Ratio 
 0.91
Revenue / Employee 
 509.67M
Employees 
 176
Market Cap 
81.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 79.84B | -66.04B | -45.27% | 
| Dec 31, 2023 | 145.88B | 16.88B | 13.09% | 
| Dec 31, 2022 | 129.00B | 38.66B | 42.80% | 
| Dec 31, 2021 | 90.34B | 35.13B | 63.64% | 
| Dec 31, 2020 | 55.20B | -17.90B | -24.49% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |